The reiteration of a Buy rating and a high price target of $200 by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Krystal Biotech. This endorsement likely reflects confidence in the company's pipeline, strategy, and market position, which could positively influence investor sentiment and potentially drive the stock price up in the short term.